Xadago gets EU nod in first for Newron
This article was originally published in Scrip
Executive Summary
The EU's CHMP has granted a positive opinion on marketing Newron Pharmaceuticals/Zambon's novel Parkinson's disease therapy safinamide as Xadago, putting it on course to become the first new chemical entity to be approved for the condition in ten years.